The Oncology Institute(US:TOI)2026-03-12 20:56Revenue Generation and Contracts - In 2025, the company generated over 46% of its revenue from patients covered by value-based contracts, predominantly in the form of capitated contracts[34]. - More than 50% of revenue in 2025 was generated from value-based contracts where payors designated affiliated providers as their preferred oncology group[67]. - The capitation arrangements involve a fixed per member per month (PMPM) payment model, aligning provider incentives with quality and efficiency of care[63]. - The TOI PCs' revenue for 2025 included approximately 16% derived from fixed fees under capitation agreements with payors[126]. - A significant portion of Patient Services revenue is dependent on a limited number of health insurance payors, with no single non-government payor accounting for more than 10% of revenue in 2025[131]. - A significant decrease in the number of capitation or fee-for-service arrangements could adversely affect revenues and results of operations[155]. Patient Care and Services - The company focuses on delivering personalized, evidence-based care while managing costs for patients and payors[31]. - The High Value Cancer Care (HVCC) program demonstrated over 25% lower median total healthcare costs from diagnosis to death[48]. - The company aims to provide access to world-class oncology care in an affordable manner to underserved populations[36]. - The average patient rating based on over 3,500 Google reviews is 4.6 out of 5 stars, indicating high patient satisfaction[52]. - The company operates specialty and retail pharmacies across five states to fill medication orders related to oncology care[28]. Growth and Expansion - The company managed a population of approximately 2.0 million patients under value-based agreements as of December 31, 2025[25]. - The company is expanding its value-based arrangements, particularly in areas with a demand for full delegation of oncology services[35]. - The company anticipates adding more TOI PC clinics through acquisitions and de novo clinic builds, enhancing market presence and capacity[56]. - The company has a robust pipeline for acquisitions, focusing on practices aligned with its value-based care philosophy[70]. - The growth strategy relies on building or acquiring new clinics to service contracts and treat patients, which involves significant risks and uncertainties[107]. Financial Performance and Risks - The Oncology Institute incurred a net loss of $60,606,000 in 2025, with a loss from operations of $36,083,000[113]. - The company anticipates increasing expenses in the future as it invests heavily in expanding its patient base and operations[113]. - A significant portion of revenue is derived from a limited number of health insurance payors, which could impact revenue if relationships are disrupted[105]. - The company faces competition for payor relationships with other healthcare organizations, which may increase costs due to ongoing consolidation in the healthcare industry[108]. - The transition from volume to value-based reimbursement models may adversely affect operations and financial results[105]. Regulatory Compliance and Legal Risks - The company is subject to various state healthcare regulations, including California Assembly Bill 1415, which requires at least 90 days' written notice before closing certain material transactions[77]. - The company is subject to federal and state healthcare regulatory laws, including the Anti-Kickback Statute and Stark Law, which impose strict compliance requirements[78][79][80]. - The company is subject to potential legal proceedings and litigation, which could materially harm its business and results of operations[173]. - The company may face significant costs and operational disruptions due to medical malpractice claims, which could strain financial resources and harm its reputation[175]. - The company is required to comply with complex fraud, waste, and abuse laws, which could lead to federal and state audits and investigations[197]. Cybersecurity and Data Privacy - Cybersecurity incidents could compromise the confidentiality and integrity of sensitive data, potentially resulting in significant costs and reputational harm[171]. - The company experienced temporary cash flow impacts due to delays in claim submissions caused by the Change Healthcare cyberattack, but does not believe the impact was material[172]. - The company collects and processes sensitive personal information, making it subject to various federal and state privacy laws, which are rapidly evolving[203]. - Violations of HIPAA can result in significant civil and criminal penalties, as well as additional oversight obligations[205]. - The company must navigate numerous state and federal laws regarding personal information processing, which complicates compliance efforts[206]. Market and Competitive Landscape - The competitive landscape includes traditional oncology practices and specialty benefit managers, with the company distinguishing itself through its integrated value-based care approach[72]. - The healthcare industry is experiencing consolidation, leading to fewer but larger payors with significant bargaining power, which may result in declining reimbursement rates[156]. - The TOI PCs' growth strategy depends on attracting new patients and retaining existing payor contracts, facing competition from other oncology providers[121]. Tax and Financial Reporting - As of December 31, 2025, the company had federal income tax NOLs of $227,510,540 and state income tax NOLs of $220,729,030 available to offset future taxable income[214]. - The deferred tax asset associated with the company's federal and state net operating losses is fully offset by a valuation allowance, limiting its impact on the effective tax rate[214]. - Future changes in tax laws or their interpretation could adversely affect the company's business, financial condition, and results of operations[215]. Operational Challenges - The company has experienced rapid growth, which has placed significant demands on management and operational resources[111]. - Increased labor costs may not be offset by rate increases due to the fixed nature of a significant percentage of revenue[159]. - The company is substantially dependent on a single source of drug supplies, which poses risks related to supply disruptions and price increases[166]. - The company must continue to invest in information technology systems to enhance patient experience and maintain competitive advantage[170].